Effect of anti-fibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burden (Reduce-MFA-DZHK25)
The REDUCE-MFA-DZHK25 trial is testing whether antifibrotic drugs can reduce cardiac scarring after TAVI and improve patient prognosis.
Munich Remote SpO2 and Heart Rate Assessment in Covid-19 patients (COVID SMART formerly MR SPOC)
In the COVID SMART trial, modern smartwatches continuously measure ECG, pulse, and oxygen saturation in the blood of COVID-19 patients and transfer these data into the hospital to get treatment advice.
Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)
The Germany-wide COVIDPREVENT trial is investigating whether the administration of the blood thinner Rivaroxaban can reduce thrombotic events such as heart attack, pulmonary embolism or stroke in CoVID-19 patients.
Stopping ACE-inhibitors in COVID-19 (ACEI-COVID-19)
The study investigates the effects on the course of COVID-19 disease when ACE inhibitors are paused or replaced by antihypertensives with a different mechanism of action in COVID-19 patients.
Cardiac Magnetic Resonance guidance of Implantable Cardioverter Defibrillator implantation in non-ischaemic dilated cardiomyopathy (CMR-ICD-DZHK23)
The CMR-ICD-DZHK23 study wants to optimise the implantation of a defibrillator in patients with non-ischemic cardiomyopathy based on fibrosis on cardiac MRI.
First prospective randomized trial to examine a differential therapeutic response in symptomatic patients with non-obstructive coronary artery disease after coronary physiological testing (EXAMINE-CAD-DZHK22)
The EXAMINE-CAD-DZHK22 study is investigating which drugs help with circulatory disorders of small heart vessels.
TranslatiOnal Registry for CardiomyopatHies-Plus (TORCH-Plus-DZHK21)
TORCH-Plus is a large-scale prospective data & biospecimen repository of patients with non-ischemic cardiomyopathies.
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-DZHK20)
BioVAT-HF-DZHK20 trial is investigating under which conditions engineered human myocardium is safe to use in the treatment of patients with end-stage heart failure.
Phosphodiesterase-5 inhibition in patients with combined pre- and postcapillary pulmonary hypertension due to heart failure with preserved ejection fraction (PASSION)
The associated DZHK study PASSION investigates whether the drug Tadalafil can reduce cardiac-related hospital admissions and mortality of patients with pulmonary hypertension due to heart failure.
Prediction of Acute Coronary Syndrome in Acute Ischemic Stroke (PRAISE-DZHK19 I DZNEB001)
The aim of the study PRAISE-DZHK19 I DZNEB001 is to establish a clinical algorithm that enables the prediction of acute coronary syndrome or heart attack in stroke patients.
Effect of Metformin in insulin resistant patients with heart failure with reduced ejection fraction (METRIS-HF-DZHK18)
The METRIS-HF-DZHK18 trial aims to find out whether improved energy metabolism can increase heart efficiency in patients with cardiac insufficiency.
Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older (SCREEN AF-DZHK15)
The SCREEN-AF study aims to improve the early detection of atrial fibrillation using a new “rhythm patch” with an integrated ECG recording unit which is applied to the patient’s chest.
Evaluating the benefit of concurrent tricuspid valve repair during mitral surgery (CTSN-TVR-DZHK14)
The aim of the study is to clarify whether it is beneficial to operate the tricuspid valve in the right heart at the same time if the mitral valve is defective, even if the right heart valve is not yet very leaky.
Validation of Cardiovascular Magnetic Resonance against Invasive Haemodynamics in Patients with Heart Failure with Preserved Ejection Fraction (Decipher HFpEF-DZHK12)
The DECIPHER HFpEF-DZHK12 study investigates whether diastolic heart failure can be better diagnosed and its causes clarified with the help of cardiovascular magnetic resonance imaging (CMR).
Exercise Training in Patients with Left Ventricular Assist Device (Ex-VAD-DZHK11)
This study is examining whether a tailored physical exercise can improve the fitness and quality of life of patients with an artificial heart.
Randomized Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality (DEDICATE-DZHK6)
The DEDICATE-DZHK6 study is investigating whether surgical or transcatheter aortic valve implantation is the superior long-term treatment option for patients with severe aortic valve stenosis.
Ultrasound evaluation of the inferior vena cava in addition to clinical assessment to guide decongestion in acute decompensated heart failure: a pilot study (CAVA-ADHF-DZHK10)
This trial is examining whether an ultrasound evaluation of the inferior vena cava in acute decompensated heart failure (ADHF) with congestion can be implemented in hospitals’ everyday routine in a large number of patients.
Cardiovascular magnetic resonance real time exercise stress testing in heart failure with preserved ejection fraction (HFpEF-stress-DZHK17)
Researchers will test in this trial whether the newly developed real-time CMR technology is suitable for the early and safe diagnosis of HFpEF.
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy (CLOSURE-AF-DZHK16)
The DZHK study CLOSURE-AF compares the benefit of the left atrial appendage closure with the best possible drug therapy for high-risk patients with atrial fibrillation.
SPIRonolactone In the Treatment for Heart Failure (SPIRIT-HF-DZHK8)
The SPIRIT-HF-DZHK8 study investigates whether the drug spironolactone can reduce the number of people with preserved ejection fraction who end up in hospital and the number of people who die from heart failure.
Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction (SMART-MI-DZHK9)
DZHK researchers from Munich test whether the use of implantable cardiac monitors with home monitoring function is more effective than conventional follow-up for detecting serious arrhythmic events in a newly identified high-risk group of patients.
Apixaban versus Phenprocoumon: oral anticoagulation plus antiplatelet therapy in patients with acute coronary syndrome and atrial fibrillation (APPROACH-ACS-AF-DZHK7)
DZHK researchers compare two therapies in patients with atrial fibrillation, who have also had a heart attack in order to find out which therapy leads to less bleedings.
Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity and mortality (FAIR-HF2-DZHK5)
The FAIR-HF2 study will be assessing whether treatment with intravenously administered ferric carboxymaltose improves the chances of survival and helps to reduce the number of hospitalisations of heart failure patients diagnosed with iron deficiency.
Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation (TOMAHAWK-DZHK4)
TOMAHAWK compares the effects of immediate coronary angiography to delayed intervention in survivors of cardiac arrest who occurred outside a hospital and without ST elevation.
Early versus emergency left ventricular assist device implantation in patients awaiting cardiac transplantation (VAD-DZHK3)
This study is expected to deliver guideline-relevant findings for the future treatment of patients with terminal heart failure.
Systolic dysfunction to congestive heart failure cohort study (TransitionCHF-DZHK2)
This cohort study explores ways of predicting when decreased cardiac performance without symptoms will develop into a clinically manifest disease.
Translational registry for cardiomyopathies (TORCH-DZHK1)
As a translational registry for cardiomyopathies, TORCH-DZHK1 collects data and biosamples from 2,300 patients with heart muscle diseases.
Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention (ISAR-PLASTER)
The study objective is to evaluate the efficacy and safety of treatment of the drug Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.
Continuation of the cohort “inflammatory cardiomyopathy” of the collaborative research centre transregio 19 (SFB/TR19) as “SFB/TR19 Plus”
The cohort study SFB/TR 19 plus investigates new diagnostic and treatment approaches for inflammatory cardiomyopathies.
Prospective, randomized trial of ticagrelor versus prasugrel in patients with acute coronary syndrome (ISAR-REACT 5)
This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes.
Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK)
Prospective randomized multicenter study comparing immediate multivessel revascularization by PCI versus culprit lesion PCI with staged non-culprit lesion revascularization in patients with acute myocardial infarction complicated by cardiogenic shock.
SORT-AF Supervised Obesity Reduction Trial for AF Ablation Patients (SORT-AF)
Prospective randomized multicenter study to evaluate the impact of weight reduction on AF recurrence after AF ablation in obese patients.
German Aortic valve RegistrY (GARY)
Prospective, controlled, multicenter registry study to evaluate the variability in structural requirements, processes, andresults for different aortic valve therapies (e.g. surgical AVR and TAVI,different prosthetic valve devices).
Evaluation of the safety and efficacy of the OPTIMIZER ® system in subjects with moderate-to-severe heart failure (FIX-HF-5C)
The study was designed to evaluate both safety and efficacy of the OPTIMIZER system in patients with moderate to severe heart failure.
Non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH-AFNET 6)
NOAH-AFNET 6 evaluates the potential benefit of oral anticoagulation treatment in patients with atrial high rate episodes.
Early treatment of atrial fibrillation for stroke prevention trial (EAST – AFNET 4)
National register for congenital heart defects (NRCHD)
The person-based register records data from patients of all age groups and with all kinds of congenital heart defects across Germany.
No entries found for search criteria